Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Xilio Therapeutics, Inc.

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-22Dec-31-21Dec-31-20Dec-31-19
   10-K10-K10-KS-1/A
Revenues  0.00.00.014.3
            Revenue growth    -100.0% 
Cost of goods sold  0.00.00.019.0
Gross profit  0.00.00.0-4.8
            Gross margin     -33.5%
Selling, general and administrative   [+]29.923.910.74.8
Research and development  59.251.243.9 
Other operating expenses   -0.5-0.19.5
EBITDA   [+]-87.3-73.1-53.4 
            EBITDA margin     -133.5%
Depreciation and amortization  1.81.51.1 
EBIT   [+]-89.1-74.6-54.4-19.0
            EBIT margin     -133.5%
Non-recurring items   0.50.1 
Other income (expense), net   [+]0.9-0.8-0.71.7
Pre-tax income  -88.2-75.8-55.2-17.3
Income taxes  0.00.00.00.0
            Tax rate  0.0%0.0%0.0%0.0%
Net income  -88.2-75.8-55.2-17.3
            Net margin     -121.4%
   
Basic EPS   [+]($3.22)($13.52)($105.42) 
Diluted EPS   [+]($3.22)($13.52)($105.42) 
   
Shares outstanding (basic)   [+]27.45.60.5 
Shares outstanding (diluted)   [+]27.45.60.5 
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy